Cynomolgus IFN-alpha/beta R1 Protein, His Tag (MALS verified)
分子別名（Synonym）
IFNAR1,IFNAR,CRF2-1,IFN-R-1,IFNAR-1
表達區(qū)間及表達系統(tǒng)（Source）
Cynomolgus IFN-alpha/beta R1 Protein, His Tag (IF1-C52H3) is expressed from human 293 cells (HEK293). It contains AA Ala 25 - Lys 437 (Accession # A0A7N9D7J0-1).
Predicted N-terminus: Ala 25
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 49.3 kDa. The protein migrates as 65-95 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>90% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
Interferon alpha/beta receptor 1 ( IFNAR1) is also known as Cytokine receptor class-II member 1, Cytokine receptor family 2 member 1 (CRF2-1), Type I interferon receptor 1, IFNAR, which belongs to the type II cytokine receptor family. IFNAR1 /IFNAR contains four fibronectin type-III domains. IFNAR1 associates with IFNAR2 to form the type I interferon receptor. IFNAR1 is receptor for interferons alpha and beta. IFNAR1 can transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.
關(guān)鍵字： IFN-alpha/beta R1;IFN-alpha R1蛋白;IFN-beta R1蛋白;ACRO;百普賽斯;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。